LCS
MURA

Levin Capital Strategies’s Mural Oncology MURA Stock Holding History

Levin Capital Strategies’s Portfolio MURA Stock Details MURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-20,000
Closed -$97.8K – 253
2024
Q1 		$97.8K Buy
+20,000
New +$97.1K 0.01% 217

Other funds holding MURA

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
AFA
Alta Fundamental Advisers New York $265M AUM 98.61% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Levin Capital Strategies's MURA Position: Q2 2024 in Review

Levin Capital Strategies sold out of Mural Oncology (MURA) in Q2 2024, closing a stake of 20,000 shares — an estimated $97.8K sold.

Levin Capital Strategies first reported a position in MURA in Q1 2024 and held it in 1 quarter. The position peaked at $97.8K in Q1 2024. 86 funds tracked by Wall St. Rank hold MURA as of Q2 2024.

  • Levin Capital Strategies reported no remaining Mural Oncology position as of Q2 2024 after selling out during the quarter.
  • Levin Capital Strategies sold 20,000 Mural Oncology shares in Q2 2024, an estimated $97.8K.
  • Levin Capital Strategies first reported a position in Mural Oncology in Q1 2024 and held it in 1 quarter.
  • Levin Capital Strategies's Mural Oncology position peaked at $97.8K in Q1 2024.
  • 86 funds tracked by Wall St. Rank held Mural Oncology as of Q2 2024.

Based on Levin Capital Strategies's 13F filing for Q2 2024, filed 7 Aug 2024.